Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis market Read more
Credit profile of Indian pharma cos to remain healthy in FY2025 despite moderation in revenue growth: ICRA Read more
Novel therapies to drive Crohn’s disease market growth across 8MM to $15 bn by 2032: GlobalData Read more